TYK2/JAK1 drugs for Psoriasis
3 tracked TYK2/JAK1 drugs in the Psoriasis race. The class explanation lives on the TYK2/JAK1 page; the full indication pipeline across every mechanism is on the Psoriasis page.
2 Phase 21 preclinical / unstaged
Head-to-head evidence: Girocitinib vs Soficitinib (ICP-332) · brepocitinib vs Girocitinib · brepocitinib vs Soficitinib (ICP-332)